Radioimmunotherapy for Peritoneal Carcinomatosis: Advances in Carcinomas

Strategic Insights -

Researchers from Memorial Sloan-Kettering Cancer Center have made significant progress in treating peritoneal carcinomatosis, a type of cancer that has significantly compromised patient survival. According to a recent study published in Cell Reports Medicine, targeted therapy using radionuclides such as alpha, beta, and Auger emitters delivered by antibodies is being actively investigated to improve the therapeutic outcome. While preclinical murine models have shown promising results, successful clinical trials are lacking. The researchers have retrospectively summarized preclinical and clinical PC studies, considering their translational potential and examining paths to development that maximize the clinical benefit of RIT in this context.

Key Takeaways:

  • Peritoneal carcinomatosis, a type of cancer characterized by the dissemination of metastatic tumor cells throughout the peritoneal cavity, has significantly compromised patient survival.
  • The standard of care for peritoneal carcinomatosis is cytoreductive surgery with or without intraperitoneal chemotherapy.
  • Research has shown that intraperitoneal chemotherapy and systemic chemotherapy have limited success in treating peritoneal carcinomatosis.
  • Targeted therapy using radionuclides such as alpha, beta, and Auger emitters delivered by antibodies is being actively investigated to improve the therapeutic outcome.
  • Preclinical murine models of PC have shown the potential of radioimmunotherapy (RIT) using various radioisotopes across a wide spectrum of antigen targets and tumor diagnoses with acceptable toxicities.
  • Successful clinical trials are lacking to support the use of RIT for peritoneal carcinomatosis.
  • The researchers have retrospectively summarized preclinical and clinical PC studies, considering their translational potential and examining paths to development that maximize the clinical benefit of RIT in this context.
  • Financial supporters for this research include Enid A. Haupt Endowed Chair, Robert Steel Foundation, NIH National Cancer Institute (NCI).
  • Additional authors for this research include Garrett M. Nash, Darren R. Veach, Steven M. Larson, Andrea Cercek, and Sarah M. Cheal.

Statistics:

  • Peritoneal carcinomatosis has compromised patient survival significantly.
  • Cytoreductive surgery with or without intraperitoneal chemotherapy is the standard of care for peritoneal carcinomatosis.
  • Intraperitoneal chemotherapy and systemic chemotherapy have shown limited success in treating peritoneal carcinomatosis (Report Date: May 21, 2025).
  • Preclinical murine models of PC have shown the potential of RIT using various radioisotopes across a wide spectrum of antigen targets and tumor diagnoses with acceptable toxicities.
  • The study was funded by Enid A. Haupt Endowed Chair, Robert Steel Foundation, and NIH National Cancer Institute (NCI).

Sources:

  • NewsRx. Reports from Memorial Sloan-Kettering Cancer Center Describe Recent Advances in Carcinomas (Radioimmunotherapy for Peritoneal Carcinomatosis: Preclinical Proof of Concept To Clinical Translation). Immunotherapy Weekly. May 21, 2025; p 3890.
  • Cell Reports Medicine. Radioimmunotherapy for Peritoneal Carcinomatosis: Preclinical Proof of Concept To Clinical Translation. 2025;6(4).
  • Nicole Aguirre, Memorial Sloan-Kettering Cancer Center, Dept. of Surgery, Colorectal Serv, New York, NY 10065, United States.